Evidence map›Paper›PMID 41756521›Full record

ArticleIJID regions2026

Global threats in local wards: Dissemination of high-risk clones resistant to last-generation cephalosporins and carbapenems in Iraqi hospitals.

Ehsan Adnan Hashim, Meriem Souguir, Véronique Métayer, Antoine Drapeau, Sana Azaiez, Hayder Ali Muhammed, Jean-Yves Madec, Marisa Haenni, Wejdene Mansour

Abstract read
In one paragraph

Article in IJID regions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ehsan Adnan HashimLaboratoire de Recherche Biophysique Métabolique et Pharmacologie Appliquée, LR12ES02, Faculté de Médecine Ibn Al Jazzar Sousse, Université de Sousse, Tunisie.
Meriem SouguirLaboratoire de Recherche Biophysique Métabolique et Pharmacologie Appliquée, LR12ES02, Faculté de Médecine Ibn Al Jazzar Sousse, Université de Sousse, Tunisie.
Véronique MétayerANSES - Université de Lyon, Unité Antibiorésistance et Virulence Bactériennes, Lyon, France.
Antoine DrapeauANSES - Université de Lyon, Unité Antibiorésistance et Virulence Bactériennes, Lyon, France.
Sana AzaiezLaboratoire de Recherche Biophysique Métabolique et Pharmacologie Appliquée, LR12ES02, Faculté de Médecine Ibn Al Jazzar Sousse, Université de Sousse, Tunisie.
Hayder Ali MuhammedVeterinary Medicine College, University of Kerbala, Kerbala, Iraq.
Jean-Yves MadecANSES - Université de Lyon, Unité Antibiorésistance et Virulence Bactériennes, Lyon, France.
Marisa HaenniANSES - Université de Lyon, Unité Antibiorésistance et Virulence Bactériennes, Lyon, France.
Wejdene MansourLaboratoire de Recherche Biophysique Métabolique et Pharmacologie Appliquée, LR12ES02, Faculté de Médecine Ibn Al Jazzar Sousse, Université de Sousse, Tunisie.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To conduct the first comprehensive molecular characterization of multidrug-resistant Gram-negative pathogens isolated from patients in six Iraqi hospitals. Methods: Samples (n = 104) were collected from outpatients across six hospitals in Iraq between March and September 2022. Bacterial isolates were identified using standard microbiological techniques. Antimicrobial susceptibility testing was performed according to EUCAST guidelines. Genomic DNA was extracted and subjected to whole-genome sequencing (WGS). Results: Over 104 samples, 42 resistant isolates were identified: Conclusions: These findings highlight the dissemination of high-risk clones resistant to expanded-spectrum cephalosporins and carbapenems in geographically diverse Iraqi hospitals, underscoring the urgent necessity to establish comprehensive national antimicrobial resistance surveillance and infection control strategies.

Indexed as

A. baumanniiEnterobacteralesIraqNDM-1P. aeruginosaST773

Identifiers

PMID41756521
PMCPMC12934271

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.